Tango Therapeutics, Inc.
TNGX
Pozycja w akcjach
#4551
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Cena akcji
$27.18
Ostatnia synchronizacja: 2026-07-31
Kapitalizacja rynkowa
$3.38B
Zmiana (1 dzień)
-1.41%
Zmiana (1 rok)
202.34%
Kraj
US
Handel Tango Therapeutics, Inc. (TNGX)
Kategoria
Healthcare
Wskaźnik P/B dla Tango Therapeutics, Inc. (TNGX)
Wskaźnik P/B na dzień October 2026 TTM: 3.25
Według najnowszych raportów finansowych i ceny akcji Tango Therapeutics, Inc., obecny wskaźnik P/B (TTM) wynosi 3.25. Na koniec 2023 wynosił 3.70.
Historia wskaźnika P/B dla Tango Therapeutics, Inc. od 2019 do 2026
Wskaźnik P/B na koniec każdego roku
| Rok | Wskaźnik P/B | Zmień |
|---|---|---|
| 2026 (TTM) | 3.25 | 92.08% |
| 2024 | 1.69 | -54.27% |
| 2023 | 3.70 | 44.94% |
| 2022 | 2.55 | 29.49% |
| 2021 | 1.97 | -79.17% |
| 2020 | 9.46 | -18.62% |
| 2019 | 11.63 | 0.00% |
Wskaźnik P/B dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/B | Różnica wskaźnika P/B | Kraj |
|---|---|---|---|
| 6.251 | 92.57% |
US
|
|
| 13.2547 | 308.33% |
US
|
|
| 4.208 | 29.63% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 90.46% |
NL
|
